• OPEN AN ACCOUNT
Indian Indices
Nifty
25,476.10 -46.40
(-0.18%)
Sensex
83,163.68 -372.40
( -0.45%)
Bank Nifty
57,213.55 -42.75
( -0.07%)
Nifty IT
38,680.85 -302.40
( -0.78%)
Global Indices
Nasdaq
44,477.29 215.52
(0.49%)
Dow Jones
6,283.97 37.45
(0.60%)
Hang Seng
39,601.95 -219.33
(-0.55%)
Nikkei 225
8,867.02 12.84
(0.15%)
Forex
USD-INR
85.73 -0.06
(-0.07%)
EUR-INR
100.55 -0.15
(-0.15%)
GBP-INR
116.58 -0.23
(-0.19%)
JPY-INR
0.59 0.00
(-0.73%)

EQUITY - MARKET SCREENER

Som Distilleries & Breweries Ltd
Industry :  Breweries & Distilleries
BSE Code
ISIN Demat
Book Value()
507514
INE480C01038
33.6450081
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SDBL
52.94
3060.22
EPS(TTM)
Face Value()
Div & Yield %
2.96
2
0
 

Lupin launches Ipratropium Bromide Nasal Solution in US market
Jul 04,2025

Lupin announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States. Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent® Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals, Inc.

Ipratropium Bromide Nasal Solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. Ipratropium Bromide Nasal Solution (Nasal Spray) 0.06% is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older.

Ipratropium Bromide Nasal Solution (RLD Atrovent®) had estimated annual sales of USD 63 million in the U.S. (IQVIA MAT May 2025).